STS/FISS Flashcards

1
Q

What 3 parameters are used to grade STS?

A
  1. differentiation
  2. MI (0-9, 10-19, >20)
  3. % necrosis (none, <50%, >50%)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the met rate for oral high-low FSA?

A

up to 20%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the met rate for dermal smooth muscle tumors?

A

0%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Which is not a common location for rhabdomyosarcoma?

a. urinary bladder
b. larynx
c. digit
d. tongue
e. myocardium

A

Digit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

T/F: Lipomas, intramuscular lipomas, infiltrative lipomas, and liposarcomas all appear similar cytologically but vary with regard to invasion/metastasis.

A

False
Lipomas - indistinct nuclei, cytoplasm resembling normal fat
Liposarcomas - increased cellularity, distinct nuclei, abundant cytoplasm with on or more droplets of fat

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What STS are hormone dependent?

A

Leiomyomas of the vagina and vulva

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How does risk of metastasis differ for leiomyosarcomas of the liver, intraabdominal, and dermal smooth muscle? What are most common sites of spread?

A

liver - 100% metastasized in one case series
intraabdominal - 50% metastasis
dermal smooth muscle - 0% metastasis

Sites: regional LN, mesentery, liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which IHC stains differentiate synovial cell sarcoma from histiocytic sarcoma?

A

Synovial: vimentin and cytokeratin
HS: CD18, CD204 (CD18 is sarcoma, CD204 specific among leukocytes for histolytic origin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What prognostic factors have been identified for synovial cell sarcoma?

A

Grade
Clinical stage
Extent of surgical treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How does MST differ for different grades of synovial cell sarcoma?

A

Grade 1: MST 48 mo
Grade 2: MST 36 mo
Grade 3: MST 7 mo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How does MST differ for clinical stage of synovial cell sarcoma? For amp vs. no amp?

A

Stage: LN mets <6 months, No LN mets >36 months
Amp: MST 850d, No amp: MST 455d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What % of dogs with synovial cell sarcoma have metastasis at time of diagnosis?

A

32%

54% at time of death - but this source may be pre-identification of periarticular HS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the staging scheme for STS?

A

Stage I: grade I or II, any size, any depth, N0, M0
Stage II: grade III, tumors <5cm any depth, tumors >5cm superficial only, N0, M0
Stage III: grade III, tumors >5cm, N0, M0
Stage IV: any grade, any size, any depth, N1 or M1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the recurrence rate of grade I, II, and III K9 STS after incomplete excision? (Dennis Vet Path 2011)

A

Grade I: 7%
Grade II: 34%
Grade III: 75%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the overall MST for K9 incompletely resected non-oral STS treated with post-op RT?

A

2270d (6.2y)
Only 540d for oral sarcomas
(control rate 80-95% at 1 year)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the reported 1 year tumor control rate for K9 STS treated with dRT alone?

A

1 year: 50% control
2 year: 33% control
50Gy dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the RR to pRT for K9 STS? Median time to progression?

A

50% RR
32 Gy dose
Median time to progression 155d
MST 309d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the median time to metastasis in K9 STS?

A

365d, occurs late in course of disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the RR of K9 STS to DOX +/- CTX?

A

23%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

The development of FISS at vaccination site is believed to be as high as?

A

1/1000

other reports as few as 1/10,000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

IHC evaluation of ISS identified expression of:

A

PDGF
EGF and it’s receptors
TGF-beta

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Lymphocytes in ISS are positive for what growth factor?

A

PDGF

Lymphocytes in non-injection site fibrosarcomas and normal LN are negative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

T/F: p53 mutations have been identified in ISS.

A

True

Anti-p53 antibodies have immunoreactivity in feline sarcomas and may play a role in predicting outcome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the median TTR following marginal resection of FISS?

A

79d

66d when surgery is with rDVM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
What is the median TTR following radical surgery of ISS?
325-419d
26
What % of patients had major surgical complications after removal of an ISS with 5cm lateral margins and two fascial planes deep? What % had local recurrence?
11% complication rate 14% recurrence 97% complete resection
27
What % of ISS recur after surgery and pre-op RT?
40-45% recurrence at median of 398-584d
28
What % of ISS recur after surgery and post-op RT? What about with addition of DOX?
``` 41% recurrence at median of 405d With DOX (and sx/RT): 28% recurrence at median of 661d ```
29
What is the reported MST for cats treated with surgery and RT for FISS?
600-1300d
30
What is the RR to DOX+/- CTS in macroscopic FISS?
39-50% RR | Median duration of 84-125d
31
What is MST for FISS cats that respond to chemo vs. not?
Responders: 242d | Non-Responders: 83d
32
What % of histopath reports (in recent retrospective study) included microscopic description for STS? What about measured margins?
Only 64.8% gave description and 59.6% gave margins! Useless.
33
What was DFI for treated vs. control dogs in CTX/piroxicam study? (Elmslie 2008)
Control - 211d | Tx - 410d
34
What dose of CTX/piroxicam was used in original STS study? What % developed SHC? (Elmslie 2008)
CTX 10 mg/m2, piroxicam 0.3 mg/kg | 10% SHC
35
Did doxorubicin provide a survival benefit for high grade STS? What was % local recurrence and metastasis? (Selting 2005)
No benefit | 23% recurrence, 44% metastasis
36
What were the imaging features of PNST on MRI? (2007)
T1 - hyperintense | T2 - isointense
37
What were findings of STS on PET scan using hypoxia tracer? What was the tracer? (Bruehlmeier 2005)
hypoxia noted in 3/6 tumors with low perfusion | tracer was 18F-fluoromisonidazole (FMISO)
38
What were the locations of rhabdomyosarcoma in horses? What were the types? (Castleman 2011)
4 tongue or head, 2 abdominal wall, 1 shoulder mm, 1 heart Types - 7 embryonal, 1 pleomorphic (4 treated with surgery or RT with no recurrence)
39
What were results of RT + DOX for incompletely excised feline STS? (Hahn 2007)
DFI with DOX longer (15.4mo) than w/o (5.7mo); no difference in survival (tumor grade/histo not reported)
40
What IHC markers were positive for feline PNST? Did they met? (Schulman 2009)
Positive for vimentin and S-100, majority positive for GFAP All negative for SMA No metastasis documented
41
What were prognostic factosr for cats treated with surgery and RT for STS? (Mayer 2009)
Anemia (PCV < 25% 308d vs. > 25% 760d) | Timing of RT (post-op did better than pre-op - pre-op may have been bigger tumors not amenable to sx)
42
What IHC marker confirmed dx of liposarcoma in cases that were not well-differentiated? (LaDoucer 2017)
Oil red O (confirmed lipid) | Previous studies also showed that this stains liposarcomas and not others
43
What protein correlated with grade and may be a diagnostic/prognostic marker for liposarcoma? (2016)
MDM2
44
How did MI affect survival time for canine STS in Dennis Vet Path 2011?
MI > 9 - 150-343d | MI < 9 - 826-1138d
45
Intratumoral microvessel density increases with ___, ___, and ___. (Luong 2006)
grade, necrosis, mitotic score | also correlated with AgNOR and increased metastasis
46
What two parameters correlated positively with grade and MI in Ettinger JAVMA 2006?
AgNOR and Ki67 | on multivariate analysis, increased AgNOR prognostic for decreased survival
47
What was response to hypofractionated RT for macroscopic STS? (Cancedda 2016)
ORR 30%, BR 100%; 10% CR, 20% PR, 70% SD; OST was 513d | note: no controls, some dogs had metronomic chemo, 50% grade 1 STS
48
What was % local recurrence and metastasis with hypofractionated RT for microscopic STS? (Kung 2014)
21% local recurrence, 23% metastasis (total was 24-32 Gy) | 50% were grade 2
49
Lawrence JAAHA 2008 - What was ORR, TTP, and OST for macroscopic STS treated to 32 Gy?
``` ORR 50% (7 PR, 1 CR) TTP 155d (5 mo) MST 309d (10.3mo) ```
50
What was the % local recurrence of STS managed in first opinion practice? (Bray 2014, Chase 2009)
Bray - 20.8% - extent of resection not associated with survival, probable bias for less aggressive tumors Chase - 27.9%
51
What % of residual tumor was identified in re-cut of incompletely excised STS? What was local recurrence and metastasis after re-cut? (Bacon 2007)
22% residual tumor | local recurrence 15%, metastasis 10%
52
What was recurrence and metastatic rate for low grade spindle cell sarcoma at or distal to elbow treated with marginal excision? (Stefanello 2008)
10.8% recurrence | 0% metastasis
53
The volume of FISS based on CT is often ___x caliper measurements.
2x
54
Beads implanted with what chemo showed 50% growth inhibition in FISS cell lines?
carboplatin
55
What adjuvant has been implicated in FISS?
aluminum
56
What was median DFI and MST following en bloc resection of FISS with 3cm margins? % tumor recurrence?
DFI 21 months MST 24 months 38.1% recurrence
57
For cats undergoing RT for microscopic FISS, how did PFI differ for finely fractionated (48-52.8 Gy) vs. coarsely fractionated (36 Gy)? (Rossi 2019)
For cats treated after removal of first-occurrence FISS, median PFI was significantly longer in finely fractionated group (1430d vs. 540d). (it did not differ for cats who had undergone multiple surgeries)
58
In a recent study, what IHC markers were positive for FISS? (Carneiro 2018)
desmin, vimentin, S-100 (95.2%), c-KIT, COX-2, and FeLV viral particles (note that, per Withrow, FeLV was NOT detected but was in this study)
59
What % of recut STS (original incomplete margins) had residual tumor? (Bacon 2007)
22%
60
What was FISS local recurrence with lateral surgical margins of 3cm and body wall resection/2 fascial planes deep?
38.1%! Yikes.
61
Does masitinib enhance radiosensitization of FISS cells? (Turek 2014)
No
62
What % of cats with FISS had objective response to SBRT? What was the median PFS and MST? (Nolan 2013)
``` 72.7% response (8/11 cats) - varied whether this was CT vs. PE PFI 242d (again, not all had CT), MST 301d ```
63
Are there any vaccines that are risk-free for FISS? (Srivastav 2012)
No
64
Does masitinib have anti-proliferative effect on FISS cells? What receptor was evaluated? (Lawrence 2012)
Yes - inhibits cell growth and PDGFR phosphorylation in both primary and metastatic FISS (in vitro).
65
What anti-angiogenic agent was used in canine STS? What was RR and unique side effects? (Sahora 2002)
thrombospondin-1 mimetic peptides 23% RR Keratitis and OA were dose-limiting toxicities
66
What was the effect of Toceranib for FISS? (Holtermann 2016)
No clinical response measurable in n=18 | tx with 3.35 mg/kg EOD
67
What was the concordance in grade between pre-treatment biopsy and excisions biopsy for STS? (Perry 2014)
59% | For the 41% that didn't agree 29% of pre-treatment biopsies underestimated the grade
68
What were the results of CCNU to treat FISS? Concerns regarding AE? (Saba 2012)
ORR 25%, PFS 60.5d; median duration response 82.5d Significant hematologic toxicity (target dose 38-60 mg m(-2) q3 weeks, lots of delays and reductions)
69
What % of cats had PR to liposomal doxorubicin and pRT? CR? (from intro in Holtermann 2016)
50% PR | 20% (2/10) CR
70
What is the expression of KIT in feline injection site sarcoma? (from intro in Holtermann 2016)
Only 9% of samples had >80% immunoreactivity for KIT - concluded that other factors likely contribute to dz progression
71
T/F: More than half of the peritumoral lesions identified on advanced imaging were deemed nonneoplastic after microscopic evaluation, and 20% of lesions were confirmed neoplastic.
True (Nemanic VSx 2016)